Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Prostate cancer
Stage/Subtype:  stage II prostate cancer
Trial Type:  Treatment
Results 1-25 of 77 for your search:
Start Over
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0924, NCI-2011-02674, CDR0000701128, PRTOG-0924_A03PAMDREVW01, NCT01368588
Modifications to Radical Prostatectomy in Improving Outcomes in Patients with Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 21 and over
Trial IDs: 11-096, NCI-2011-02377, NCT01407263
Phase 3 Study of ProstAtak™ Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PrTK03, NCI-2012-01912, NCT01436968
Proton Beam or Intensity-Modulated Radiation Therapy in Treating Patients with Low or Low-Intermediate Risk Prostate Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: 11-497, NCI-2012-01144, NCT01617161
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR102931, NCI-2013-02187, 2012-004322-24, ARN-509-003, NCT01946204
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-14, NCI-2013-02393, NCT02003924
Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 17712, NCI-2015-00347, 2013-003820-36, NCT02200614
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-13, NCI-2015-00824, NCT02319837
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ANZUP1303, NCI-2015-01658, ACTRN12614000126617, NCT02446444
Magnetic Resonance Spectroscopic Imaging in Finding Tumors in Patients with Stage I-III Prostate Cancer Planning to Undergo Prostate Surgery
Status: Active
Phase: Phase II, Phase I
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: 2006-0516, NCI-2011-00517, PC061612, NCT00464724
Stereotactic Body Radiation Therapy and Hormone Therapy in Treating Patients with Localized Intermediate-Risk Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J11157, NCI-2013-01332, CIR00008893, NA_00067963, NA_00067963/CIR00003978, NCT01517451
Study of a Recombinant Adenovirus to Treat Localized Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 50 to 80
Trial IDs: MTG-REIC-PC003, NCI-2014-01003, NCT01931046
High-Dose Brachytherapy in Treating Patients with Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: PROS0065, NCI-2015-00089, 350, NCT02346253
Stereotactic Body Radiation Therapy with Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients with Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Not specified
Trial IDs: UW14083, NCI-2015-00950, 2015-0395, NCT02470897
Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 85
Trial IDs: J07122, NCI-2010-02020, JHOC-J07122, JHOC-NA_00010227, NCT00670046
Hypofractionated Image-Guided Radiation Therapy In Treating Patients with Localized Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J0859, NCI-2010-02069, NA_00019393, NA_00019393 / CIR00008106, NCT00809991
High Dose Rate Brachytherapy in Treating Patients with Endometrial, Cervical, Lung, Breast, or Prostate Cancer
Status: Active
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 18 to 90
Trial IDs: 09-C-0100, NCI-2013-01448, 090100, 302844, P08407, NCT00924027
Vaccine Therapy in Treating Patients With Prostate Cancer Previously Treated With Surgery or Radiation Therapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 06-070, NCI-2011-01874, NCT00970203
Hypofractionated Stereotactic Body Radiation Therapy in Patients With Low- or Intermediate-Risk Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 09-031, NCI-2011-02495, NCT00977860
Hypofractionated Stereotactic Body Radiotherapy in Treating Patients With Localized Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 09-10-081, NCI-2010-01667, NCT01059513
Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Intermediate Risk Prostate Cancer: Feasibility Study
Status: Active
Phase: Phase II
Type: Treatment
Age: 50 to 75
Trial IDs: PCa004, NCI-2016-00068, NCT01226576
Antiandrogen Therapy with or without Axitinib before Surgery in Treating Patients with Previously Untreated Prostate Cancer with Known or Suspected Lymph Node Metastasis
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: 2011-0231, NCI-2015-01711, NCI-2011-02749, NCT01409200
Intensity Modulated Radiation Therapy With Hypofractionated Radiosurgical Boosts in Treating Patients With Localized Prostate Cancer
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2009-599, NCI-2013-00673, NCT01618851
PI3K inhibitor BKM120 in Treating Patients With High-Risk, Localized Prostate Cancer Undergoing Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 85
Trial IDs: 115516, NCI-2013-01830, CBKM120ZUS26T, UCSF CC# 115516, NCT01695473
Start Over